科学图书馆
-
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelorM Verdoiaab, M Nardinb, R Gioscia et al. -
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary InterventionD Sibbing, D Aradi, D Alexopoulos et al.
-
Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II StudyMW Krucoff , P Urban, J-F Tanguay et al.
-
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialHahn JY, Song YB, SMART-DATE investigators et al.
-
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS studyChen Y, Yin T, Xi S et al.
-
Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision MedicinePatel KV, Pandey A, de Lemos JA et al.
-
Polymer-based or Polymer-free Stents in Patients at High Bleeding RiskS Windecker, A Latib, the ONYX ONE Investigators et al.
-
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trialNatsuaki M, Morimoto T, Kimura T et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
